SCHEMBL1494847

SCHEMBL1494847

Cc1ccn2cc(-c3cccc(NC(=O)c4sc(-c5ccccc5)nc4C)c3)nc2c1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.72
SMN1; SMN2 Q16637 8/20 0.72
HPGD P15428 4/20 0.72
MAPK1 P28482 2/20 0.72
KDM4E B2RXH2 9/20 0.66
RAB9A P51151 8/20 0.66
NPC1 O15118 4/20 0.66
GFER P55789 2/20 0.62
POLB P06746 3/20 0.56
LMNA P02545 2/20 0.55
TP53 P04637 2/20 0.51
PARP1 P09874 1/20 0.50
NR1H4 Q96RI1 1/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1494576 0.91 KDM4E (0.68) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL4728109 0.84 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL2740004 0.78 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL1494791 0.77 GFER (0.79) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL9926314 0.76 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL2740002 0.75 TP53 (0.70) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL2740003 0.75 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
Hydrochloric Acid SCHEMBL3328848 0.75 RAB9A (0.73) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL14484044 0.73 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E
SCHEMBL14825244 0.72 HPGD (0.80) ALDH1A1SMN1; SMN2HPGDMAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486945-B2 Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system Ivachtchenko, Alexandre Vasilievich (US) 2013-07-16 US disclosed
US-20110053915-A1 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM ALLA CHEM, LLC (US) 2011-03-03 US disclosed
US-20110053915-A1 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM ALLA CHEM, LLC (US) 2011-03-03 US disclosed
WO-2009077956-A2 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM ALLA CHEM, LLC (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053915-A1 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM SHH, SMO, GLI1 ALDH1A1 410/4885SMN1; SMN2 4057/4885HPGD 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.